Neil Stahl - Aug 2, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research and Development
Signature
/s/**Neil E. Stahl
Stock symbol
REGN
Transactions as of
Aug 2, 2024
Transactions value $
-$7,030,122
Form type
4
Date filed
8/6/2024, 04:03 PM
Previous filing
Feb 28, 2024
Next filing
Aug 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $13.1M +23.6K +46.35% $555.67 74.6K Aug 2, 2024 Direct
transaction REGN Common Stock Tax liability -$20.2M -18.4K -24.71% $1,093.49 56.2K Aug 2, 2024 Direct
holding REGN Common Stock 5.85K Aug 2, 2024 By 401(k) Plan
holding REGN Common Stock 4.61K Aug 2, 2024 by Spouse as Trustee

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -23.6K -34.44% $0.00 45K Aug 2, 2024 Common Stock 23.6K $555.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.